Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer

British Journal of Cancer

Volumn 89, Issue 4, 2003, Pages 630-633

  Lordick, F ^a   Von Schilling, C ^a   Bernhard, H ^a   Hennig, M ^b   Bredenkamp, R ^a   Peschel, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Docetaxel; Irinotecan; Oesophageal cancer

Indexed keywords

CISPLATIN; DOCETAXEL; IRINOTECAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0041733716     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601168     Document Type: Article

References (11)

1. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C (2000) Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 18: 1116-1123
2. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220
3. Conroy T, Etienne PL, Adenis A, Wagener DJT, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J for the European Organization for Research Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 14: 164-170
4. Couteau C, Risse ML, Ducreux M, Lefresne-Soulas F, Riva A, Lebecq A, Ruffié P, Rougier P, Lokiec F, Bruno R, Armand JP (2000) Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol 18: 3545-3552
5. Gehan EA (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353
6. Hainsworth JD, Burris III HA, Erland JB, Thomas M, Greco FA (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164-2168
7. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest N Drugs 20: 95-99
8. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598
9. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834
10. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzales G, Kelsen DP (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270-3275
11. Murren JR, Blum K, Gallipoli M, McKeon A, Rich R (2001) Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. Oncology (Huntington) 15 (Suppl 1): 25-30